Cambridge, Massachusetts-based iTeos Therapeutics Inc. (ITOS:NASDAQ) reported Q3 2023 financial results and upcoming clinical catalysts, noted Wedbush Securities analyst Dr. David Nierengarten in a November 7 research report.
The key near-term catalysts will be Phase 2 data in 2024 for iTeos' lead asset, TIGIT inhibitor belrestotug, in combination with PD-1 inhibitor dostarlimab from GlaxoSmithKline (GSK) in NSCLC and head and neck squamous cell carcinoma (HNSCC) patients.
Per the analysts, the belrestotug-dostarlimab combo could be differentiated given prior belrestotug monotherapy data and recent positive dostarlimab results versus pembrolizumab.
Beyond NSCLC and HNSCC, belrestotug combination trials are underway in multiple myeloma, plus triplets adding experimental GSK CD96 and PVRIG inhibitors.
For A2A receptor antagonist inupadenant, iTeos is enrolling in a Phase 2 study in lung cancer and plans to start a Phase 1/2 study of inupadenant with pipeline asset EOS-984 in 2024.
The Wedbush analysts highlighted iTeos' "healthy balance sheet" funding operations through 2026 upcoming data readouts for all three clinical programs.
With shares trading below cash value, the firm sees significant upside potential and reiterates an Outperform rating with a US$33 price target.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
Disclosures for WedBush, ITeos Therapeutics, November 7, 2023
Analyst Certification We, David Nierengarten, Dennis Pak and Martin Fan, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.
Company Specific Disclosures
This information is subject to change at any time.
1. WS makes a market in the securities of iTeos Therapeutics.
Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures *WS changed its rating system from (Strong Buy/ Buy/ Hold/ Sell) to (Outperform/ Neutral/ Underperform) on July 14, 2009. Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to [email protected]. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019.
OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm
Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–7 of this report for analyst certification and important disclosure information. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.
